%0 Journal Article
%T The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100£żU/mL
%A Ling Gao
%A Louise Traylor
%A Markolf Hanefeld
%A Wolfgang Landgraf
%J Archive of "Cardiovascular Diabetology".
%D 2017
%R 10.1186/s12933-017-0548-0
%X Dyslipidaemia is a major contributor to the increased risk of cardiovascular disease (CVD) associated with type 2 diabetes (T2D). This study aimed to characterize the extent of lipid-lowering therapy use and its impact on lipid and glycaemic outcomes in people with T2D uncontrolled on oral agents who were enrolled in insulin glargine 100 units/mL (Gla-100) randomized controlled trials (RCTs)
%K Type 2 diabetes
%K Cardiovascular disease
%K Lipid control
%K Statins
%K Clinical trials
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438574/